Stephens Inc Castle Biosciences Inc Transaction History

Stephens Inc

$6.94 Billion
Q2 2025

A detailed history of Stephens Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Stephens Inc holds 11,386 shares of CSTL stock, worth $224,987. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,386

Previous 13,639 16.52%

Holding current value

$224,987

Previous $273,000 15.02%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 29, 2025	SELL	$15.8 - $21.98 $35,597 - $49,520	-2,253 Reduced 16.52%	11,386 $232,000
Q1 2025 May 01, 2025	SELL	$18.76 - $32.72 $15,008 - $26,176	-800 Reduced 5.54%	13,639 $273,000
Q4 2024 Jan 28, 2025	SELL	$26.52 - $34.67 $17,397 - $22,743	-656 Reduced 4.35%	14,439 $384,000
Q3 2024 Oct 28, 2024	SELL	$17.4 - $31.47 $150,997 - $273,096	-8,678 Reduced 36.5%	15,095 $430,000
Q2 2024 Aug 06, 2024	SELL	$18.84 - $24.94 $206,505 - $273,367	-10,961 Reduced 31.56%	23,773 $517,000
Q1 2024 May 15, 2024	SELL	$18.06 - $25.3 $159,740 - $223,778	-8,845 Reduced 20.3%	34,734 $769,000
Q4 2023 Feb 13, 2024	SELL	$12.19 - $22.43 $650,604 - $1.2 Million	-53,372 Reduced 55.05%	43,579 $940,000
Q3 2023 Nov 14, 2023	SELL	$13.28 - $20.3 $145,376 - $222,224	-10,947 Reduced 10.15%	96,951 $1.64 Million
Q2 2023 Aug 14, 2023	BUY	$11.66 - $26.0 $383,369 - $854,854	32,879 Added 43.83%	107,898 $1.48 Million
Q1 2023 May 15, 2023	BUY	$19.47 - $28.49 $416,404 - $609,315	21,387 Added 39.88%	75,019 $1.7 Million
Q4 2022 Jan 25, 2023	BUY	$18.08 - $30.0 $160,134 - $265,710	8,857 Added 19.78%	53,632 $1.26 Million
Q3 2022 Nov 02, 2022	SELL	$22.51 - $34.32 $16,319 - $24,882	-725 Reduced 1.59%	44,775 $1.17 Million
Q2 2022 Aug 03, 2022	BUY	$16.0 - $45.99 $728,000 - $2.09 Million	45,500 New	45,500 $999,000

Others Institutions Holding CSTL

# of Institutions

190

Shares Held

26.7M

Call Options Held

9.5K

Put Options Held

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $520M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account